Imagion Biosystems Limited is pleased to advise that the Renounceable Rights Issue announced on 25 March 2020 (“Offer”) has closed oversubscribed and raised $2.05 million. To accommodate some of the excess demand, the Company has agreed to raise an additional $0.96 million on the same terms as the Offer (“Follow-On Placement”).
Read the announcement “Imagion Rights Issue Oversubscribed Raising $3 Million“.
Corporate Updates: $3M fundraising led by CPS Capital to be completed in early December Filing of IND for MagSense® HER2 Phase 2 Study Immediate Priority
Imagion Biosystems (ASX: IBX) (Company), is pleased to announce the Company has received $3 million of firm commitments through a highly successful capital raising. The
Open a copy of this presentation deck from our ASX announcement HERE. Video transcript: Mel: Good morning, everyone. Thank you for attending the investor presentation
We’re on a mission to make cancer more detectable.
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance